Lantern Pharma Inc logo

LTRN

Lantern Pharma Inc

$5.09

Earnings Summary

Revenue
$0Mn
Net Profits
$-2.32Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Lantern Pharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2021. On a quarterly growth basis, Lantern Pharma Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Lantern Pharma Inc’s net profit fell -177.95% since last year same period to $-2.32Mn in the Q2 2021. On a quarterly growth basis, Lantern Pharma Inc has generated 5.54% jump in its net profits since last 3-months.

Net Profit Margins:

Lantern Pharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2021. On a quarterly growth basis, Lantern Pharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Lantern Pharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.49
EPS Estimate Current Year
-0.49

Highlights

EPS Estimate Current Quarter:

Lantern Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a 9.26% jump from last quarter’s estimates.

EPS Estimate Current Year:

Lantern Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.49.

Key Ratios

Key ratios of the Lantern Pharma Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.41
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-0.21

Highlights

Earning Per Share (EPS):

Lantern Pharma Inc’s earning per share (EPS) fell -95.24% since last year same period to -0.41 in the Q2 2022. This indicates that the Lantern Pharma Inc has generated -95.24% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Lantern Pharma Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lantern Pharma Inc’s return on equity (ROE) stands at -0.21.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-08
-0.52
-0.41
21.15%
2022-05-03
-0.29
-0.38
-31.03%

Company Information

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to its pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging its technology to uncover, rescue and develop abandoned or failed drugs. Its current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. It believes that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Its team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible.

Organisation
Lantern Pharma Inc
Headquarters
1920 McKinney Avenue, Dallas, TX, United States, 75201
Employees
14
Industry
Commercial Services

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*